IL315814A - Crystalline forms of immunomodulators - Google Patents

Crystalline forms of immunomodulators

Info

Publication number
IL315814A
IL315814A IL315814A IL31581424A IL315814A IL 315814 A IL315814 A IL 315814A IL 315814 A IL315814 A IL 315814A IL 31581424 A IL31581424 A IL 31581424A IL 315814 A IL315814 A IL 315814A
Authority
IL
Israel
Prior art keywords
compound
formula
mixture
solution
solvent
Prior art date
Application number
IL315814A
Other languages
English (en)
Hebrew (he)
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Publication of IL315814A publication Critical patent/IL315814A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL315814A 2017-09-29 2018-09-27 Crystalline forms of immunomodulators IL315814A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2017/104485 WO2019061324A1 (en) 2017-09-29 2017-09-29 CRYSTALLINE FORMS OF IMMUNOMODULATORS
PCT/US2018/053052 WO2019067678A1 (en) 2017-09-29 2018-09-27 CRYSTALLINE FORMS OF IMMUNOMODULATORS

Publications (1)

Publication Number Publication Date
IL315814A true IL315814A (en) 2024-11-01

Family

ID=65900346

Family Applications (2)

Application Number Title Priority Date Filing Date
IL315814A IL315814A (en) 2017-09-29 2018-09-27 Crystalline forms of immunomodulators
IL273463A IL273463A (en) 2017-09-29 2020-03-19 Crystalline forms of immunomodulators

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL273463A IL273463A (en) 2017-09-29 2020-03-19 Crystalline forms of immunomodulators

Country Status (14)

Country Link
US (5) US11040948B2 (enExample)
EP (1) EP3687534A4 (enExample)
JP (2) JP7783688B2 (enExample)
KR (2) KR20200060402A (enExample)
CN (2) CN111163772A (enExample)
AU (2) AU2018341583B2 (enExample)
BR (1) BR112020006137A2 (enExample)
CA (1) CA3076013A1 (enExample)
EA (1) EA202090500A1 (enExample)
IL (2) IL315814A (enExample)
MY (1) MY201378A (enExample)
PH (1) PH12020550133A1 (enExample)
SG (1) SG11202002378XA (enExample)
WO (2) WO2019061324A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA030155B1 (ru) 2013-09-06 2018-06-29 Ауриген Дискавери Текнолоджиз Лимитед Производные 1,2,4-оксадиазола в качестве иммуномодуляторов
KR102708045B1 (ko) 2015-03-10 2024-09-23 오리진 온콜로지 리미티드 면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물
WO2019061324A1 (en) 2017-09-29 2019-04-04 Curis Inc. CRYSTALLINE FORMS OF IMMUNOMODULATORS
JP7618445B2 (ja) 2017-10-11 2025-01-21 オーリジーン オンコロジー リミテッド ３－置換１，２，４－オキサジアゾールの結晶形態
CN111372584A (zh) 2017-11-03 2020-07-03 奥瑞基尼探索技术有限公司 Tim-3和pd-1途径的双重抑制剂
EA202090749A1 (ru) 2017-11-06 2020-08-19 Ориджен Дискавери Текнолоджис Лимитед Способы совместной терапии для иммуномодуляции
SG11202106250RA (en) 2018-12-20 2021-07-29 Impact Selector International Llc Downhole tool for connecting with a conveyance line

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3227725A (en) 1962-04-17 1966-01-04 Union Carbide Corp Certain 3,5-disubstituted 1,2,4-oxadiazole compounds
TW201311B (enExample) 1991-06-17 1993-03-01 Hoffmann La Roche
CA2143246C (en) 1994-03-16 2000-08-22 Thierry Godel Imidazodiazepines
EP2360254A1 (en) 1999-08-23 2011-08-24 Dana-Farber Cancer Institute, Inc. Assays for screening anti-pd-1 antibodies and uses thereof
CA2442066C (en) 2001-04-02 2005-11-01 Wyeth Pd-1, a receptor for b7-4, and uses therefor
WO2002086083A2 (en) 2001-04-20 2002-10-31 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
WO2003042402A2 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
GB0204159D0 (en) 2002-02-22 2002-04-10 British Biotech Pharm Metalloproteinase inhibitors
US7595048B2 (en) 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
AR046787A1 (es) 2003-12-05 2005-12-21 Bristol Myers Squibb Co Agentes antimigrana heterociclicos
US7585881B2 (en) 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
EP1593671A1 (en) 2004-03-05 2005-11-09 Graffinity Pharmaceuticals AG DPP-IV inhibitors
WO2006067532A1 (en) 2004-12-24 2006-06-29 Prosidion Ltd G-protein coupled receptor agonists
DK2161336T4 (en) 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
WO2006133216A2 (en) 2005-06-06 2006-12-14 Smithkline Beecham Corporation 4-substituted arylamine derivatives and their use in pharmaceutical compositions
US20090042926A1 (en) 2005-12-20 2009-02-12 Jason Imbriglio Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment
EP1999119A2 (en) 2006-02-15 2008-12-10 Abbott Laboratories Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
WO2008011557A2 (en) 2006-07-20 2008-01-24 Borchardt Allen J Heteroaryl inhibitors of rho kinase
SI2076501T1 (sl) * 2006-09-25 2016-05-31 Ptc Therapeutics, Inc. Kristalinične oblike 3-(5-(2-florofenil)-1,2,4) oksadiazol-3-il)-benzojske kisline
NZ582150A (en) 2007-06-18 2012-08-31 Msd Oss Bv Antibodies to human programmed death receptor pd-1
EP2178531A4 (en) 2007-07-02 2012-01-11 Yu Ming METHODS AND COMPOSITIONS, TARGETS FOR COMBINED CANCER TREATMENTS
US7868001B2 (en) 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
CL2009000400A1 (es) 2008-02-22 2010-09-10 Irm Llc Compuestos heterociclicos derivados de 3-fenil-1,6- naftiridin-2-ona; moduladores de la actividad cinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastornos alergicos, trastornos autoinmunes, neoplasias, rechazo en trasplante de organos, entre otras.
WO2010033701A2 (en) 2008-09-19 2010-03-25 Genzyme Corporation Inhibitors of sphingosine kinase 1
US20120088747A1 (en) 2008-10-30 2012-04-12 Saunders Jeffrey O Sulfonamide containing compounds and uses thereof
HRP20170908T1 (hr) 2008-12-09 2017-09-22 F. Hoffmann - La Roche Ag Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
WO2011137587A1 (en) 2010-05-06 2011-11-10 Hutchison Medipharma Limited Cytokine inhibitors
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2012129564A2 (en) 2011-03-24 2012-09-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Proteasome chymotrypsin-like inhibition using pi-1833 analogs
CN103732238A (zh) 2011-06-08 2014-04-16 奥瑞基尼探索技术有限公司 用于免疫调节的治疗性化合物
KR20140069235A (ko) 2011-09-27 2014-06-09 노파르티스 아게 돌연변이체 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
WO2013132317A1 (en) 2012-03-07 2013-09-12 Aurigene Discovery Technologies Limited Peptidomimetic compounds as immunomodulators
EP2831108A1 (en) 2012-03-29 2015-02-04 Aurigene Discovery Technologies Limited Immunomodulating cyclic compounds from the bc loop of human pd1
KR101947702B1 (ko) 2012-10-04 2019-02-14 다나-파버 캔서 인스티튜트 인크. 인간 단클론 항-pd-l1 항체 및 사용 방법
ES2824024T3 (es) 2012-10-10 2021-05-11 Sangamo Therapeutics Inc Compuestos modificadores de células T y usos de los mismos
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
US9220710B2 (en) 2013-01-09 2015-12-29 Gilead Sciences, Inc. Therapeutic compounds
KR20150131224A (ko) 2013-03-14 2015-11-24 노파르티스 아게 돌연변이 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
WO2014147586A1 (en) 2013-03-22 2014-09-25 Novartis Ag 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh
EA030155B1 (ru) 2013-09-06 2018-06-29 Ауриген Дискавери Текнолоджиз Лимитед Производные 1,2,4-оксадиазола в качестве иммуномодуляторов
CU24345B1 (es) * 2013-09-06 2018-05-08 Aurigene Discovery Tech Ltd Derivados de 1,3,4-oxadiazol y 1,3,4-tiadiazol como inmunomoduladores
SG11201601844TA (en) 2013-09-13 2016-04-28 Beigene Ltd Anti-pd1 antibodies and their use as therapeutics and diagnostics
GB2516515B8 (en) 2013-12-04 2016-10-05 Intelligent Growth Solutions Ltd Automated arrangement to grow plants under lighting in a vertical tower
WO2016073470A1 (en) * 2014-11-04 2016-05-12 The University Of Kansas Lkb1-ampk activators for therapeutic use in polycystic kidney disease
KR102708045B1 (ko) 2015-03-10 2024-09-23 오리진 온콜로지 리미티드 면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물
CN107427476A (zh) 2015-03-10 2017-12-01 奥瑞基尼探索技术有限公司 作为免疫调节剂的3‑取代的‑1,2,4‑噁二唑和噻二唑化合物
BR112017019306A2 (pt) 2015-03-10 2018-05-08 Aurigene Discovery Technologies Limited compostos de 1,3,4-oxadiazol e tiadiazol como imunomoduladores
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
CA3004138A1 (en) 2015-11-03 2017-05-11 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and tim-3 and their uses
WO2018047143A1 (en) 2016-09-12 2018-03-15 Aurigene Discovery Technologies Limited Vista signaling pathway inhibitory compounds useful as immunomodulators
WO2018051254A1 (en) 2016-09-14 2018-03-22 Aurigene Discovery Technologies Limited Cyclic substituted-1,2,4-oxadiazole compounds as immunomodulators
EA201990997A1 (ru) 2016-10-20 2019-08-30 Ориджин Дискавери Текнолоджиз Лимитед Двойные ингибиторы vista и путей pd-1
WO2019061324A1 (en) 2017-09-29 2019-04-04 Curis Inc. CRYSTALLINE FORMS OF IMMUNOMODULATORS
JP7618445B2 (ja) 2017-10-11 2025-01-21 オーリジーン オンコロジー リミテッド ３－置換１，２，４－オキサジアゾールの結晶形態
CN111372584A (zh) 2017-11-03 2020-07-03 奥瑞基尼探索技术有限公司 Tim-3和pd-1途径的双重抑制剂
EA202090749A1 (ru) 2017-11-06 2020-08-19 Ориджен Дискавери Текнолоджис Лимитед Способы совместной терапии для иммуномодуляции

Also Published As

Publication number Publication date
IL273463A (en) 2020-05-31
AU2018341583A1 (en) 2020-04-02
US20240182433A1 (en) 2024-06-06
AU2018341583B2 (en) 2024-04-04
US20200247766A1 (en) 2020-08-06
US11040948B2 (en) 2021-06-22
KR20240115921A (ko) 2024-07-26
BR112020006137A2 (pt) 2020-10-13
US12252475B2 (en) 2025-03-18
US11643401B2 (en) 2023-05-09
US20210380544A1 (en) 2021-12-09
US11939306B2 (en) 2024-03-26
JP2023134541A (ja) 2023-09-27
CN117209444A (zh) 2023-12-12
EP3687534A4 (en) 2021-06-30
CN111163772A (zh) 2020-05-15
MY201378A (en) 2024-02-21
US20250188045A1 (en) 2025-06-12
KR20200060402A (ko) 2020-05-29
AU2024201938A1 (en) 2024-04-11
EA202090500A1 (ru) 2020-11-03
PH12020550133A1 (en) 2021-02-08
WO2019067678A1 (en) 2019-04-04
EP3687534A1 (en) 2020-08-05
JP2021501127A (ja) 2021-01-14
SG11202002378XA (en) 2020-04-29
WO2019061324A1 (en) 2019-04-04
CA3076013A1 (en) 2019-04-04
US20230167077A1 (en) 2023-06-01
JP7783688B2 (ja) 2025-12-10

Similar Documents

Publication Publication Date Title
IL315814A (en) Crystalline forms of immunomodulators
JP2022176979A5 (enExample)
IL318981A (en) Method for preparing crystalline forms of 1,2,4-oxadiazole-3-methyl-1,2-dione
US9309210B2 (en) Crystalline form of cabazitaxel and process for preparing the same
US8901322B2 (en) Crystalline forms of cabazitaxel and process for preparation thereof
JP2021501127A5 (enExample)
US10889545B2 (en) Crystalline form of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine salt
AU2017304887B2 (en) Polymorphic forms of belinostat and processes for preparation thereof
JP2020536872A5 (enExample)
WO2016107289A1 (zh) 制备索非布韦晶型6的方法
KR102835134B1 (ko) 이사부코나조늄 설페이트의 정제 방법
US20210087194A1 (en) Chemical Process for Preparing Imidazopyrrolidinone Derivatives and Intermediates Thereof
JP2019172635A (ja) アジルサルタン微細結晶の製造方法
WO2011113788A1 (en) Process for purifying 3-difluoromethyl-1-methyl-1h-pyrazole-4-carboxylic acid
JP2007501274A (ja) カベルゴリンの多形体
US10538493B2 (en) Process for the purification of 1-(4-chlorophenyl)pyrazol-3-ol
EP3697794A1 (en) Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
JP2001518106A (ja) １，３−ジ置換２−ニトログアニジンの製造法
JP2017517531A (ja) ピペリジン−４−カルボチオアミドの製造
KR20220039771A (ko) 소타글리플로진의 결정질 형태 ii를 제조하는 방법
WO2019086434A1 (en) Process for the synthesis of 2-benzhydryl-3 quinuclidinone
KR20210090225A (ko) 에피나코나졸의 제조 방법
EP2283010A1 (en) Process for preparing intermediate compound for synthesizing an antiulcerant
MXPA04008944A (es) Procedimiento para derivados de triterpeno.
KR20190082874A (ko) 간소화된 다루나비르 제조 절차